MDT-AP-3265
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 7.9
- sex
- M
- new_clusters
- C1
- umap1_2d
- 4.760159495
- umap2_2d
- 0.742564392
- umap1_3d
- 1.147302474
- umap2_3d
- -3.735981531
- umap3_3d
- -1.028314575
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.410
- G2M_CHECKPOINT+0.390
- MITOTIC_SPINDLE+0.300
- SPERMATOGENESIS+0.230
- WNT_BETA_CATENIN_SIGNALING+0.130
- BILE_ACID_METABOLISM+0.100
- MYC_TARGETS_V2+0.090
- TGF_BETA_SIGNALING+0.040
- HEME_METABOLISM+0.010
- MTORC1_SIGNALING+0.010
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- IL6_JAK_STAT3_SIGNALING-0.470
- INTERFERON_GAMMA_RESPONSE-0.430
- TNFA_SIGNALING_VIA_NFKB-0.430
- HYPOXIA-0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.420
- ALLOGRAFT_REJECTION-0.400
- INFLAMMATORY_RESPONSE-0.400
- INTERFERON_ALPHA_RESPONSE-0.380
- OXIDATIVE_PHOSPHORYLATION-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3325 | Med | Medulloblastoma | 0.908 |
| 2 | s_150324_3b | EPN | Posterior Fossa EPN | 0.908 |
| 3 | SRR10900006 | — | — | 0.903 |
| 4 | BS_TE0GVDNG | medulloblastoma | — | 0.896 |
| 5 | SJEPD031175_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.895 |
| 6 | BS_9V633J1X | medulloblastoma | — | 0.894 |
| 7 | TCGA-21-1082-01A-01R-A96U-41 | — | cohortSQ1 | 0.893 |
| 8 | MDT-AP-0314 | Med | Medulloblastoma | 0.890 |
| 9 | BS_9V633J1X | Med | Medulloblastoma | 0.888 |
| 10 | SRR975551 | — | — | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.090 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.040 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.010 | Inavolisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.010 | Remibrutinib | — uncovered |